Summary. Insulin antibodies expressed as insulin binding capacity of IgG were determined in 50 Type 1 (insulin-dependent) diabetic children who have been treated with monocomponent porcine insulin from the onset of the disease. During the follow-up period of 0.5-5.5years (mean+SD: 3.2+_ 1.6 years), 26 out of 50 patients (52%) developed detectable insulin antibodies. These patients had significantly lower maximal C-peptide responses to a standardized breakfast 9 months after onset of diabetes (mean 0.24pmol/ml, p< 0.001) than those without insulin antibodies (mean 0.47 pmol/ml). In addition, patients with antibodies showed both significantly higher insulin requirements at 9 months (p < 0.05), and shorter remissions (t9< 0.01) than those without. It is concluded that even 'small' amounts of insulin antibodies may be biologically significant and have negative effects on B-cell function and metabolic balance.
Subjects and methods
The study included all Type t (insulin-dependent) children (26 boys and 24 girls) in the Link6ping area with onset of diabetes between 1 July 1976 and 1 April 1981. Their age at onset varied between 3-16 years (mean _ SD: 10.1 +_ 3.5 years).
All children were treated from diagnosis with monocomponent insulin (Novo), usually a combination of short-and intermediate-acting, twice daily. In addition, we prescribed a regulated diet and recommended regular physical exercise. The patients and/or parents were taught to determine glycosuria by the Clinitest two-drop method in single-voided urinary fractions two to four times every day, and to register the results in a diary which was shown to the doctor at the visits to hospital every 2-3 months. Since 1980, an increasing number of children have used blood glucose monitoring as well.
Methods
Blood samples were drawn at diagnosis just before the first insulin injection, and then after 3 days, 1, 3, 6, 9, 18 and 24 months and thereat'-ter once a year, always with the patient fasting before the morning insulin injection. At some of these occasions (after 3, 9, 18 months), the islet B-cell response to a standardized breakfast was tested [15] . The follow-up period varied between 0.5-5.5 years (mean 3.2 + 1.6 years). In all samples antibodies were measured as the insulin-binding capacity of IgG according to Christiansen [3] . Total immunoreactive insulin and C-peptide levels were determined as described by Heding [8, 9] .
Partial remission was defined by the International Study Group of Diabetes in Children and Adolescents [t] as a continuous period early after onset without glycosuria and with an insulin requirement of < 0.5 IU/kg body weight per 24 h.
HLA-DR types were determined by conventional methods [4] . For example in the case of the relation between insulin antibodies and maximal C-peptide response at 9 months (Table 1) , the correlation coefficient serves as an estimate of the correlation between C-peptide and insulin dose in samples comprising individuals who are alike with respect to the remaining background variables. The t value is obtained when testing the null-hypothesis stating that any correlation between insulin antibodies and maximal C-peptide response is of a random nature when other background variables are held constant. The p values yield information on the frequency of a partial correlation of the size to be observed supposing the relationship is purely random. o, g-0 3 9
Stat&tical methods
Duration of diabetes (months) Fig.2 . Serum C-peptide at onset of diabetes, and maximal serum Cpeptide response after a standardized breakfast after 3 months' and 9 months' duration. Comparison between patients who did and those who did not develop insulin antibodies within that period. O = no insulin antibodies; 9 = detectable insulin antibodies within 9 months
Results
At onset of diabetes no child had detectable insulin antibodies (detection limit 0.050mU/ml), but within I month antibodies were detectable in 4 out of 44 (9%), after 3 months in 12 out of 38 (32%) and after 1 year in 20 out of 39 (52%) (Fig. 1) . During the follow-up period, 26patients (52%) had detectable insulin antibodies (> 0.050 mU/ml), 18 patients (36%) had levels >0A00mU/ml. Only six patients (12%) had levels > 0.500 mU/ml. Total immunoreactive insulin reached 10-880 mU/1 (100 _+ 147 mU/1). Forty-three were HLA-DR typed, of whom seven were positive for DR3 but not DR4, 14 for DR4 but not DR3, and 21 for DR3 and DR4. Only one patient was neither DR3-nor DR4-positive. Antibodies tended to increase more rapidly in patients with HLA-DR4 than in patients with other DRtypes, although not significantly so (p<0A). However when B-cell function was studied at 9 months' duration two out of eight DR3 patients had antibodies, compared with four out of 14 DR4 patients (NS). The C-peptide values at onset and the maximal Cpeptide values after standardized breakfast at 3 and 9 months' duration are shown in Figure 2 . At onset, there was no difference in C-peptide between those who developed insulin antibodies within 9 months and those who did not. After 9 months the maximal C-peptide response to a standardized breakfast varied between 0.05 and 1.13 pmol/ml (mean 0.40 ___ 0.27 pmol/ ml). This value was significantly lower in patients who developed detectable insulin antibodies (p<0.001; Table 1 , Fig.2 ). These patients also had significantly shorter partial remission (p<0.02) and higher insulin requirement at 9 months' duration (p<0.05). The same picture was seen if the limit IgG > 0.100 mU/ml was used (Table 2) . Taking age at onset, sex, and C-peptide values into consideration in the multiple regression analysis, detectable insulin antibodies appeared to be the factor with the strongest relation to duration of partial remission (r= 0.37, p< 0.02).
Discussion
This study confirms that patients treated from the onset of diabetes with monocomponent insulin usually get no or very small amounts of insulin antibodies in comparison with the levels usually seen after treatment with, for example, conventional lente insulins [10] . However, the negative correlation with B-cell function was clear in patients with insulin antibodies just above the detection limit 0.050 mU/ml. No further impairment of B-cell function could be seen when we looked at patients with levels above 0.100mU/ml. High levels of antibodies were seen in so few patients that statistical analysis was difficult, but it was evident that those with very high levels of antibodies had no greater decline in B-cell function than those with levels just above detection limit. That the decline in B-cell function really was associated with insulin antibodies was shown by including the Cpeptide levels at onset in the statistical analysis, when the demonstrated differences proved to be independent of other factors important for B-cell function, such as sex, age at onset and HLA type. In accordance with the negative relationship between low C-peptide levels at 9 months and detectable insulin antibodies, we also saw a highly significant correlation between low C-peptide response and high insulin requirement (p< 0.001). Patients with detectable insulin antibodies also had a significantly shorter partial remission, evident when other factors of importance for the duration of remission were kept constant in the statistical analysis. Christiansen's method [3] is regarded as a sensitive method compared with others [2, 16, 18, Heding, personal communication] and insulin antibodies just above the detection limit may seem to be a small amount. However, our results indicate that these amounts of antibodies may be biologically significant, perhaps as deleterious for B-cell function as much higher amounts. The mechanism is unclear. We have earlier speculated upon whether the insulin antibodies could have some kind of 'exhausting' effect by binding endogenously secreted insulin and proinsulin [6, 7, 15, 19] . Another explanation could be that insulin antibodies and complexes of antibodies act as antigens contributing to the inflammatory reactions in the islets of Langerhans. Other studies have shown that injecting crystalline immunogenic insulins into non-diabetic animals causes insulitis which leads to abnormal tolerance and even diabetes in some animals [5, 6, 11, 12] . One could speculate upon whether causation in the opposite direction is equally possible, in other words that in the absence of endogenous insulin secretion exogenous insulin is more immunogenic. However, as shown in Figure 2 , in patients who developed antibodies endogenous insulin secretion was as good as in those who did not, both at onset and after 3 months. This finding also contradicts the idea that it is the patients with the most impaired B-cell function at the beginning of insulin therapy who produce more antibodies. The tendency for patients with HLA-DR4 to develop insulin antibodies more rapidly requires confirmation. Such a tendency might result in some way from HLA-associated heterogeneity of the disease, or alternatively it might reflect an independent genetic effect on immune response.
A shorter partial remission and high insulin requirement in patients with detectable insulin antibodies may at least partly be explained by the decreased endogenous insulin secretion. Futhermore, it is quite understandable that large amounts of insulin antibodies leading to high total immunoreactive insulin levels make it difficult or impossible to imitate the rapid changes of free insulin seen in the physiological state, which explains why the metabolic balance is disturbed and the insulin requirement increases [17] . If this mechanism is involved in our patients it follows that even a 'moderately' increased amount of immunoreactive insulin interferes with the insulin treatment and metabolic balance.
In conclusion, we have shown that many diabetic children and adolescents produce insulin antibodies within one month to a few years when treated with the least immunogenic and purest porcine insulin available. These barely detectable amounts of insulin antibodies may have a negative effect on B-cell function, which could be an important mechanism in the continuing destruction of B cells after the diagnosis of diabetes. In addition, even 'small' amounts of insulin antibodies are associated with a shorter partial remission and an increased insulin requirement.
